DeepMed Research

BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread

Completed

Conditions: Cancer of the Head
Cancer of the Neck
Cancer of Head and Neck

First Posted Date: 2018-06-26

Last Posted Date: 2022-02-10

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 262

Registration Number: NCT03569436

Locations: 🇯🇵
Local Institution, Tokyo, Japan

Study of the Sudden Heart Failure Participant Population in the US

Withdrawn

Conditions: Heart Decompensation

Interventions: Other: Non-Interventional

First Posted Date: 2018-06-25

Last Posted Date: 2022-07-08

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT03566264

Locations: 🇺🇸
Bristol-Myers Squibb, Princeton, New Jersey, United States
🇺🇸
Local Institution, Princeton, New Jersey, United States

An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Rifampin
Drug: BMS-986224

First Posted Date: 2018-06-20

Last Posted Date: 2018-08-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT03563950

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects

Phase 1

Completed

Conditions: Systemic Lupus Erythematosus
Healthy Participants

Interventions: Drug: BMS-986165
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2018-05-30

Last Posted Date: 2020-01-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 84

Registration Number: NCT03541564

Locations: 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States

A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot

Completed

Conditions: Venous Thromboembolism (VTE)

First Posted Date: 2018-05-11

Last Posted Date: 2022-02-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 35756

Registration Number: NCT03521908

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

Phase 2

Terminated

Conditions: Urinary Bladder Neoplasms

Interventions: Biological: Nivolumab
Biological: BCG
Drug: BMS-986205

First Posted Date: 2018-05-08

Last Posted Date: 2023-06-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 142

Registration Number: NCT03519256

Locations: 🇺🇸
Local Institution - 0001, Baltimore, Maryland, United States
🇺🇸
Local Institution - 0044, Los Angeles, California, United States
🇺🇸
Local Institution - 0140, Houston, Texas, United States

and more 81 locations

An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function

Phase 1

Completed

Conditions: Liver Dysfunction
Liver Insufficiency
Hepatic Failure
Myocardial Failure
Heart Decompensation
Cardiac Failure
Congestive Heart Failure

Interventions: Drug: BMS-986231

First Posted Date: 2018-05-04

Last Posted Date: 2020-08-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT03515980

Locations: 🇵🇱
KO-MED Centra Kliniczne Lublin, Lublin, Poland
🇭🇺
Semmelweis Egyetem Altalanos Orvostudomanyi Kar, Budapest, Hungary
🇵🇱
BioVirtus Centrum Medyczne, Jozefow, Poland

and more 1 locations

A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)

Conditions: Heart Failure

First Posted Date: 2018-05-03

Last Posted Date: 2018-06-20

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 99209

Registration Number: NCT03515655

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules

Phase 1

Completed

Conditions: Healthy Volunteers

First Posted Date: 2018-04-26

Last Posted Date: 2020-01-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 94

Registration Number: NCT03509883

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Completed

Conditions: Chronic Myeloid Leukemia in Chronic Phase
Philadelphia Chromosome
Chronic Myeloid Leukemia

Interventions: Other: Non-Interventional

First Posted Date: 2018-04-26

Last Posted Date: 2022-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 463

Registration Number: NCT03509896

Locations: 🇨🇳
Local Institution, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy